Log In
BCIQ
Print this Print this
 

Cosopt, dorzolamide/timolol maleate

  Manage Alerts
Collapse Summary General Information
Company Merck & Co. Inc.
DescriptionTopical carbonic anhydrase inhibitor and adrenergic receptor beta (ADRB) blocker
Molecular Target Carbonic anhydrase II (CAII) ; Adrenergic receptor beta (ADRB)
Mechanism of ActionAdrenergic receptor beta (ADRB) agonist; Carbonic anhydrase inhibitor
Therapeutic ModalitySmall molecule: Combination
Latest Stage of DevelopmentMarketed
Standard IndicationOcular hypertension
Indication DetailsTreat intraocular pressure
Regulatory Designation
PartnerAkorn Inc.;
Mundipharma International Ltd.;
Santen Pharmaceutical Co. Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

4

$805.6M

$705.6M

$100.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today